Question 1

What is tirzepatide?

Accepted Answer

Tirzepatide is one molecule acting on two receptors at once. A 2022 systematic review describes it as a new molecule capable of controlling glucose blood levels by combining the dual agonism of GIP and GLP-1 receptors. Both are incretin receptors, which means they answer to hormones the gut releases after a meal. The same review sets out what those hormones do in the body. GIP and GLP-1 are released in the intestine in response to nutrient intake and stimulate pancreatic beta cell activity secreting insulin. One of them also works on appetite, and the review notes that GLP-1 in particular reduces food intake and delays gastric emptying, the speed at which the stomach passes food along. So the design copies two signals the body already uses. It was built for blood sugar first, and the weight results followed from that same biology.

Question 2

What is a Mounjaro injection for?

Accepted Answer

Mounjaro is the trade name the molecule first sold under. A 2023 pharmacy journal article titled New Drug: Tirzepatide (Mounjaro) describes tirzepatide as a novel dual GIP receptor and GLP-1 receptor agonist. The same molecule, a different name on the carton. What it was first cleared for was blood sugar, not weight. The 2022 systematic review records that the Food and Drug Administration approved tirzepatide subcutaneous injections as monotherapy or combination therapy, with diet and physical exercise, to achieve better glycemic blood levels in patients with diabetes. Glycemic simply means relating to blood sugar. The trade name matters for a single reason. It tells you the vial was made to a filed specification and dispensed by a pharmacy, which is not true of everything sold under that chemical name.

Question 3

Does tirzepatide actually work for weight loss?

Accepted Answer

Yes, and the evidence is the kind most compounds covered here never get. In SURMOUNT-1, 2,539 adults with a body-mass index of 30 or more, or 27 or more with a weight-related complication, were assigned to once-weekly tirzepatide at 5 mg, 10 mg or 15 mg or to placebo for 72 weeks. The mean percentage change in weight at week 72 was -15.0% with 5 mg, -19.5% with 10 mg and -20.9% with 15 mg, against -3.1% with placebo. A second trial put the same question to Chinese adults, who received 10 mg or 15 mg or placebo plus a lifestyle intervention for 52 weeks. The mean change in body weight at week 52 was -13.6% with 10 mg and -17.5% with 15 mg, against -2.3% with placebo. Both numbers are group averages across thousands of randomised participants, not an outcome any individual experienced. Both also combined the weekly injection with a supervised lifestyle programme, so the percentages describe a combination rather than a compound alone. The amounts belong to the dosage page. What the trials recorded as a result, and what a group average can say about one person, is taken separately at the Tirzepatide results page.

Question 4

How far into human testing has tirzepatide gone?

Accepted Answer

Further than anything else covered on this site. The diabetes programme alone ran five trials, and a 2023 pharmacy review records that evidence from five SURPASS clinical trials has demonstrated that tirzepatide has potent glucose lowering and weight loss with adverse effects comparable to GLP-1 receptor agonists. The obesity programme is separate and also phase 3. One trial assessed weight management in people living with obesity and type 2 diabetes. Another enrolled 783 participants in an open-label lead-in on the maximum tolerated dose of 10 or 15 mg for 36 weeks before randomising them. The follow-up is long for this field. Participants with obesity and prediabetes received their assigned dose for a total of 176 weeks, followed by a 17-week off-treatment period. Three years of exposure, measured in a controlled trial, is evidence a reader cannot get for most compounds.

Question 5

What did tirzepatide do for blood sugar?

Accepted Answer

Glucose control in the diabetes trials was tracked through HbA1c, its standard marker, which is the proportion of haemoglobin with sugar attached. SURPASS-1 ran 40 weeks in 478 adults whose type 2 diabetes was not controlled by diet and exercise alone and who had never used an injectable diabetes therapy. At 40 weeks all tirzepatide doses were superior to placebo for changes from baseline in HbA1c, fasting serum glucose and bodyweight. In those patients the investigators summarised the result as robust improvements in glycaemic control and bodyweight, without increased risk of hypoglycaemia, which is blood sugar falling too low. A separate 40-week trial compared the compound with semaglutide in 1,879 patients. Mean HbA1c change ran to -2.01, -2.24 and -2.30 percentage points with 5 mg, 10 mg and 15 mg, against -1.86 with semaglutide. What that comparison is and is not worth is set out on the comparison page.

Question 6

What else has tirzepatide been tested for?

Accepted Answer

Two conditions beyond diabetes and weight have published phase 3 results. In a pair of 2024 sleep apnoea trials, adults with moderate-to-severe obstructive sleep apnoea and obesity were assigned to the maximum tolerated dose of 10 mg or 15 mg or to placebo for 52 weeks. In the arm not already using a breathing machine, the mean change in the apnoea-hypopnoea index at week 52 was -25.3 events per hour with tirzepatide and -5.3 with placebo. The second is heart failure. A 2025 trial randomly assigned 731 patients with heart failure, an ejection fraction of at least 50% and a body-mass index of at least 30, to tirzepatide or placebo for at least 52 weeks. Cardiovascular death or a worsening heart-failure event occurred in 36 patients on tirzepatide and 56 on placebo. Every participant in both trials also carried obesity, so neither separates the compound from the weight it removed. Each outcome the programme has measured, from blood sugar through sleep apnoea to heart failure, is taken one at a time at the Tirzepatide benefits page.

Question 7

What is the weight that comes off made of?

Accepted Answer

Part of it is lean tissue, and that has been measured rather than guessed at. A substudy of SURMOUNT-1 scanned 160 of the 2,539 participants with dual-energy X-ray absorptiometry, a scan that separates fat from lean mass, at baseline and week 72. The change in body weight, fat mass and lean mass from baseline to week 72 was -21.3%, -33.9% and -10.9% with tirzepatide, against -5.3%, -8.2% and -2.6% with placebo. Fat came off at roughly three times the proportional rate of lean tissue, and lean tissue still went. The authors report that the proportion of body weight lost as fat or lean mass was relatively consistent across subgroups, including comparisons by sex and by age. Whether that proportional lean loss carries any consequence for strength or physical function across years is a different question, and no analysis among the research behind this page within this programme has followed participants far enough to settle it.

Question 8

What happens when you stop taking tirzepatide?

Accepted Answer

The weight comes back. A withdrawal trial ran 783 adults through 36 weeks of open-label tirzepatide, by which point the 670 who finished had a mean weight reduction of 20.9%, then randomly assigned them to continue or switch to placebo for 52 more weeks. The mean percent weight change from week 36 to week 88 was -5.5% with tirzepatide against 14.0% with placebo. The placebo group did not simply stop losing. They put weight back on, and the authors concluded that withdrawing tirzepatide led to substantial regain of lost weight while continued treatment maintained and augmented the initial reduction. That regain happened inside a controlled trial where both groups continued the diet and activity programme and remained under regular supervision by study staff. Read the figure as a floor rather than as a worst case, which is the opposite of the way most summaries present it.

Question 9

Does tirzepatide keep working over three years?

Accepted Answer

The long data exist, and they are informative precisely because they are not flat. At 176 weeks the mean percent change in body weight among participants on tirzepatide was -12.3% with 5 mg, -18.7% with 10 mg and -19.7% with 15 mg, against -1.3% with placebo. Set those beside the same trial's week-72 figures of -15.0%, -19.5% and -20.9%. Every amount is smaller at three years, so average weight drifted upward while people were still injecting. The same analysis reports a markedly lower risk of progression to type 2 diabetes than with placebo across the period. Read the two findings together rather than picking one. Weight plateaued and partly rebounded on treatment, and the metabolic outcome still separated from placebo. Those are different measurements of different things.

Question 10

Is tirzepatide still being studied?

Accepted Answer

Yes, and well outside weight and diabetes. One phase 2 trial registered as Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity is recruiting. Lipotoxicity means harm from fat building up in tissues that do not normally store it. Two more are open. One is registered as Tirzepatide in Obesity-Driven Endometrial Cancer, and a phase 4 trial registered as Tirzepatide in PWS, HO and GNSO is recruiting as well. A study of tirzepatide in patients with obesity at a hospital in Paraguay is registered but has not begun, and one trial in Latino adults with obesity was withdrawn. A 2022 systematic review noted that other clinical trials are currently underway to evaluate its use in other diseases. But a registration is a plan, not a result, and none has reported.

Question 11

Is there a tirzepatide pill?

Accepted Answer

No trial among the research behind this page of tirzepatide has used anything but an injection under the skin. Every phase 3 result on this page came from a weekly subcutaneous dose, and the approval the FDA granted in 2022 was specifically for tirzepatide subcutaneous injections. That is an absence of evidence rather than a verdict against tablets. Nothing published establishes what an oral version would do in a person, because no trial among the research behind this page has given one to anyone. So when a capsule or a drop under the tongue is offered under this name, the accurate description is that no trial result on this page applies to it. Those percentages were produced by weekly injections, and they belong to weekly injections.

Question 12

Is tirzepatide the same thing as a research peptide?

Accepted Answer

The molecule is one question. The supply chain is another, and people asking usually mean the second. A 2024 review in JAMA groups tirzepatide with liraglutide and semaglutide as nutrient-stimulated hormone-based medicines that mimic the actions of enteropancreatic hormones that modify central appetite regulation. That is the family it sits in. What differs between a pharmacy vial and one from a research chemical supplier is not the name on it. It is whether anyone independent has checked that the contents match that name. Every figure on this page came from material supplied for a registered trial. No analysis among the research behind this page has measured the purity or identity of tirzepatide bought outside the approved supply, which leaves that unmeasured rather than settled. The buying page covers what can actually be checked.

Question 13

Is compounded tirzepatide the same as the approved version?

Accepted Answer

No, and the gap between them is a regulatory one before it is a chemical one. Approval attaches to a particular injection made by a named manufacturer to a filed specification. A compounded vial is prepared by a pharmacy and carries no FDA-approved label, so nothing the approval established about the branded injection has been established about what is in it. The enforcement record shows what that distinction looks like. FDA recall listings include tirzepatide injections at 30 mg/mL in pre-filled syringes from a Colorado firm, and a 60 mg/10 mL lyophilised vial, meaning freeze-dried powder, from a Florida firm. Both were Class II recalls citing lack of assurance of sterility. Three more, filed on one day in July 2025, covered tirzepatide combined with niacinamide at three strengths, and those cited lack of processing controls instead. Ten such recalls sit in the record between 2024 and 2026.

Question 14

Is tirzepatide approved, and what for?

Accepted Answer

Yes, for two separate indications, and they were granted separately. The 2022 systematic review records the Food and Drug Administration approving tirzepatide subcutaneous injections as monotherapy or combination therapy, with diet and physical exercise, for better glycemic blood levels in patients with diabetes. The weight use came afterwards. A 2023 JAMA review lists six medicines approved by the Food and Drug Administration for long-term use in obesity and names tirzepatide among them. A 2025 review states that it is approved at the same doses, 5, 10 and 15 mg, for both type 2 diabetes and chronic weight management. So the approval covers one injection, two uses and three amounts. Two things follow from that. Approval is a fact about a made product, not about a molecule. Sharing the name does not carry it over to a compounded syringe or to a research chemical listing.

Question 15

What is documented about side effects?

Accepted Answer

One paragraph, because this has its own page. Adverse effects of this class, according to a 2024 JAMA review of obesity medicines, include nausea in 28% to 44% of patients, diarrhoea in 21% to 30% and constipation in 11% to 24%. Those are class figures rather than tirzepatide-specific ones, and the trials themselves record how many people walked away: in SURPASS-1, 66 of 478 participants, or 14%, discontinued the study drug, and in a 2022 insulin add-on trial discontinuation ran at 10%, 12% and 18% across the 5 mg, 10 mg and 15 mg groups against 3% on placebo. The share stopping rose with the amount, a pattern a summary percentage hides. What is documented, who was excluded, and what the long record holds are set out at the Tirzepatide safety page.

Question 16

How does tirzepatide work?

Accepted Answer

It switches on both receptors, but not evenly. A 2020 laboratory study worked out how much of each receptor the compound ties up at the doses used in trials. It found a greater degree of engagement of tirzepatide for the GIP receptor than the GLP-1 receptor, corroborating an imbalanced mechanism of action. It also acts differently at each one. The same work reports that tirzepatide mimics the actions of native GIP at the GIP receptor but shows bias at the GLP-1 receptor. Bias means it favours one of the two signals that receptor can send, and plays down the other. In isolated clumps of pancreatic cells, a protein called beta-arrestin1 limited the insulin response to GLP-1 but not the response to GIP or tirzepatide. Does that imbalance explain why the weight figures beat those of single-receptor molecules? No experiment in this record has demonstrated that the imbalance is the reason. The explanation arrived after the clinical results rather than ahead of them.

Tirzepatide